Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vitamin price fixing

This article was originally published in The Tan Sheet

Executive Summary

European Commission levies $751.3 mil. fine against eight firms Nov. 21 "for participating in...distinct secret market-sharing and price-fixing cartels affecting vitamin product" from September 1989 to February 1999. Firms charged are Hoffmann-La Roche, BASF, Aventis, Merck KgaA, Solvay Pharmaceuticals, Daiichi Pharmaceutical, Eisai and Takeda Chemical Industries. Since Hoffmann-La Roche "participated in all the cartels," it received the highest fine of $405.9 mil. (1 Euro=$.878). EC decision comes roughly two years after the U.S. Department of Justice levied criminal fines of more than $850 mil. (1"The Tan Sheet" Sept. 13, 1999, p. 4)...

You may also be interested in...

Citric acid price fixing

Five suppliers fined $120.5 mil. (€1=$.887) by European Commission for anti-competitive, market-sharing practices from 1991-1997, EC announces Dec. 5. Firms involved are Archer Daniels Midland, Haarmann & Reimer, Cerestar Bioproducts, Hoffmann-La Roche and Jungbunzlauer. Roche incurred largest portion, roughly $56.3 mil. Each firm was charged in proportion to its size, market share, "gravity" and "duration" of infringement, EC notes. Fines for ADM ($35.5 mil.) and Roche were increased because they acted as cartel co-leaders. Roche recently was fined more than $400 mil. by EC as one of eight firms in separate vitamin price-fixing cartel (1"The Tan Sheet" Nov. 26, In Brief)...

Takeda, Eisai, Daiichi Plead Guilty In Criminal "Vitamin Cartel" Case

Three Japanese vitamin manufacturers have agreed to plead guilty to charges associated with "a worldwide conspiracy to raise and fix prices and allocate market shares for certain vitamins sold in the U.S. and elsewhere," the Department of Justice announced Sept. 9.

QUOTED. 12 April 2020. Mike Dale.

Abbott has received two CE marks, expanding access to the company’s TriClip minimally invasive tricuspid valve repair technology and its market-leading Xience everolimus-eluting coronary stent. Mike Dale, senior vice president of Abbott’s structural heart business, explained the significance of the news.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts